×

Mersana Therapeutics to Present Late-Breaking Poster at AACR Annual Meeting 2015

CAMBRIDGE, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present two posters, including a late-breaker with data from its lead immunoconjugate candidate, at the American Association for Cancer Research (AACR) Annual Meeting taking place April 18-22 at the Pennsylvania Convention Center in Philadelphia, PA.

The poster details are as follows:

Title: Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species
Abstract Number: 641
Date: Sunday, April 19, 2015
Time: 1:00 p.m. – 5:00 p.m. ET
Presenter: Natasha Natalya Bodyak, Ph.D., Senior Director, Biology, Mersana
Late-Breaker Title: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
Abstract Number: LB-231
Date: Tuesday, April 21, 2015
Time: 1:00 p.m. – 5:00 p.m. ET
Presenter: Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer, Mersana

In addition, Asana BioSciences will present data developed in collaboration with Mersana.

The poster details are as follows:

Title: ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug conjugate, causes complete regression in multiple solid tumor models
Abstract Number: 1693
Date: Monday, Apr 20, 2015
Time: 8:00 a.m. – 12:00 p.m.
Presenter: Roger A. Smith, Ph.D., Vice President, Asana BioSciences

About Mersana Therapeutics

Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences.

CONTACT: Media Contact 6 Degrees Tony Plohoros tplohoros@6degreespr.com (908) 940-0135Source:Mersana Therapeutics, Inc.